Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Want to cut your energy bills? Here’s how five experts are doing it 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
ATLANTA, March 03, 2017 -- Alimera Sciences (NASDAQ:ALIM), a leader in the commercialization, research and development of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the 37th Annual Cowen Health Care Conference, to be held March 6-8, 2017 at The Boston Marriott Copley Place, Boston, Massachusetts. Alimera Sciences' presentation will take place Monday, March 6, 2017, at 4:40 PM Eastern Time.
A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of the Company's website at www.alimeraciences.com. A replay of the conference presentation will also be available.
About Alimera Sciences
Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the commercialization, research and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
Contact: CG Capital 877.889.1972 [email protected] cg.capital
